Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

References

• Gupta RK, Gregson J, Parkin N, et al. Hiv-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: A systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18(3):346–355.
   PubMed Web of Science ®Google Scholar
• Hiv drug resistance report. World Health Organization, United States Centers for Disease Control and Prevention, The Global Fund to Fight AIDS, Tuberculosis and Malaria; 2017.
   Google Scholar
• Cuevas JM, Geller R, Garijo R, et al. Extremely high mutation rate of hiv-1 in vivo. PLoS Biol. 2015;13(9):e1002251.
   PubMed Web of Science ®Google Scholar
• Abram ME, Ferris AL, Shao W, et al. Nature, position, and frequency of mutations made in a single cycle of hiv-1 replication. J Virol. 2010;84(19):9864–9878.
   PubMed Web of Science ®Google Scholar
• Achieng L, Riedel DJ. Dolutegravir resistance and failure in a kenyan patient. J Infect Dis. 2018;219(1):165-167.
   Google Scholar
• Pham HT, Goring ME, Mesplède T. Reply to achieng and riedel. J Infect Dis. 2018;219(1):167-169.
   Google Scholar
• Zhang WW, Cheung PK, Oliveira N, et al. Accumulation of multiple mutations in vivo confers cross-resistance to new and existing integrase inhibitors. J Infect Dis. 2018;218 (11):1773–1776.
   PubMed Web of Science ®Google Scholar
• Wohl D, Yazdanpanah Y, Baumgarten A, et al. A phase 3, randomized, controlled clinical trial of bictegravir in a fixed-dose combination, b/f/taf, vs dtg/abc/3tc in treatment-naïve adults at week 96. San Francisco: IDWeek; 2018.
   Google Scholar
• Guidelines for the use of antiretroviral agents in hiv-1-infected adults and adolescents. U.S. Department of Health and Human Services; 2018. AIDSinfo website: https://aidsinfo.nih.gov/guidelines.
   Google Scholar
• Brown T. Fda approves ibalizumab for multidrug-resistant hiv-1. Medscape; 2018.
   Google Scholar
• Sheikh V, Murray JS, Sherwat A. Ibalizumab in multidrug-resistant hiv - accepting uncertainty. N Engl J Med. 2018;379(7):605–607.
   PubMed Web of Science ®Google Scholar
• Vincent W, Robert S, Sara M, et al. Antiviral activity of efda against nrti-sensitive and -resistant strains of hiv-2. Seattle, WA: CROI; 2017.
   Google Scholar
• Jay G, Carolyn M, Carol F, et al. Mk-8591 concentrations at sites of hiv transmission and reduction. Seattle, WA: CROI; 2017.
   Google Scholar
• Cahn P, Fink V, Patterson P. Fostemsavir: A new cd4 attachment inhibitor. Curr Opin HIV AIDS. 2018;13(4):341–345.
   PubMed Web of Science ®Google Scholar
• Kozal M, Aberg J, Pialoux G, et al. Phase 3 study of fostemsavir in heavily treatment-experienced hiv-1-infected participants: day 8 and week 24 primary efficacy and safety results (brighte study, formerly 205888/ai438–047). EACS Conference; Milan, Italy; 2017.
   Google Scholar
• Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable hiv-integrase inhibitor for the treatment of hiv-aids infection. J Med Chem. 2008;51(18):5843–5855.
   PubMed Web of Science ®Google Scholar
• Anker M, Corales RB. Raltegravir (mk-0518): A novel integrase inhibitor for the treatment of hiv infection. Expert Opin Investig Drugs. 2008;17(1):97–103.
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant hiv infection: week 96 results of the benchmrk 1 and 2 phase iii trials. Clin Infect Dis. 2010;50(4):605–612.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the hiv-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with hiv-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46(2):125–133.
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the hiv-1 integrase inhibitor raltegravir (mk-0518) in treatment-experienced patients with multidrug-resistant virus: A phase ii randomised controlled trial. Lancet. 2007;369(9569):1261–1269.
   PubMed Web of Science ®Google Scholar
• Hicks C, Gulick RM. Raltegravir: the first hiv type 1 integrase inhibitor. Clin Infect Dis. 2009;48(7):931–939.
   PubMed Web of Science ®Google Scholar
• Elion R, Molina JM, Ramon Arribas Lopez J, et al. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with hiv-1 infection: 96-week results. J Acquir Immune Defic Syndr. 2013;63(4):494–497.
   PubMed Web of Science ®Google Scholar
• Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant hiv type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis. 2010;201(6):814–822.
   PubMed Web of Science ®Google Scholar
• Metifiot M, Vandegraaff N, Maddali K, et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation y143. Aids. 2011;25(9):1175–1178.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Henry K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir df vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir df for initial treatment of hiv-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;62(5):483–486.
   PubMed Web of Science ®Google Scholar
• Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of hiv-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63(1):96–100.
   PubMed Web of Science ®Google Scholar
• Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir df vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir df for initial treatment of hiv-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e121–124.
   PubMed Web of Science ®Google Scholar
• Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir df versus single-tablet regimen efavirenz/emtricitabine/tenofovir df for initial treatment of hiv-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e118–120.
   PubMed Web of Science ®Google Scholar
• Anstett K, Brenner B, Mesplede T, et al. Hiv drug resistance against strand transfer integrase inhibitors. Retrovirology. 2017;14(1):36.
   PubMedGoogle Scholar
• Castagna A, Ferrara M, Galli L, et al. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with hiv-1 integrase strand inhibitor-resistant virus. J Antimicrob Chemother. 2018;73(1):177–182.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant hiv type 1 infection: 24-week results of the viking study. J Infect Dis. 2013;207(5):740–748.
   PubMed Web of Science ®Google Scholar
• Akil B, Blick G, Hagins DP, et al. Dolutegravir versus placebo in subjects harbouring hiv-1 with integrase inhibitor resistance associated substitutions: 48-week results from viking-4, a randomized study. Antivir Ther. 2015;20(3):343–348.
   PubMed Web of Science ®Google Scholar
• Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant hiv-1: 24-week results of the phase iii viking-3 study. J Infect Dis. 2014;210(3):354–362.
   PubMed Web of Science ®Google Scholar
• Anstett K, Mesplede T, Oliveira M, et al. Dolutegravir resistance mutation r263k cannot coexist in combination with many classical integrase inhibitor resistance substitutions. J Virol. 2015;89(8):4681–4684.
   Web of Science ®Google Scholar
• Ferrari D, Spagnuolo V, Manca M, et al. Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients. Antivir Ther. 2018 Oct 24; doi: 10.3851/IMP3275 [Epub ahead of print].
   PubMedGoogle Scholar
• Wijting I, Rokx C, Boucher C, et al. Dolutegravir as maintenance monotherapy for hiv (domono): A phase 2, randomised non-inferiority trial. Lancet HIV. 2017;4(12):e547–e554.
   PubMed Web of Science ®Google Scholar
• Pham HT, Labrie L, Wijting IEA, et al. The s230r integrase substitution associated with virus load rebound during dolutegravir monotherapy confers low-level resistance to integrase strand-transfer inhibitors. J Infect Dis. 2018;218(5):698–706.
   PubMed Web of Science ®Google Scholar
• Oliveira M, Ibanescu RI, Anstett K, et al. Montreal Primary HIVCSG: selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 2018;15(1):56.
   PubMedGoogle Scholar
• Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with hiv-1 infection (latte-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–1510.
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Hoffmann C. Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis. Curr Opin HIV AIDS. 2018;13(4):334–340.
   PubMed Web of Science ®Google Scholar
• McPherson TD, Sobieszczyk ME, Markowitz M. Cabotegravir in the treatment and prevention of human immunodeficiency virus-1. Expert Opin Investig Drugs. 2018;27(4):413–420.
   PubMed Web of Science ®Google Scholar
• Hassounah SA, Mesplede T. Where are we with injectables against hiv infection and what are the remaining challenges? Expert Rev Anti Infect Ther. 2018;16(2):143–152.
   PubMed Web of Science ®Google Scholar
• Trezza C, Ford SL, Spreen W, et al. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS. 2015;10(4):239–245.
   PubMed Web of Science ®Google Scholar
• Sillman B, Bade AN, Dash PK, et al. Creation of a long-acting nanoformulated dolutegravir. Nat Commun. 2018;9(1):443.
   PubMedGoogle Scholar
• Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of hiv infection in adults: 2018 recommendations of the international antiviral society-USA panel. JAMA. 2018;320(4):379–396.
   PubMed Web of Science ®Google Scholar
• Gilead. Biktarvy® (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use. Initial u.S. Approval. 2018.
   Google Scholar
• Markham A. Bictegravir: first global approval. Drugs. 2018;78(5):601–606.
   PubMed Web of Science ®Google Scholar
• Nakamoto H, Yamada H, Watanabe Y. Pharmacological properties and clinical findings of new drugs for the treatment of hiv-1, ftc/taf 200/10 and 200/25 mg (descovy((r)) combination tablet lt and ht. Nihon Yakurigaku Zasshi. 2017;150(5):251–260.
   PubMedGoogle Scholar
• Gibson AK, Shah BM, Nambiar PH, et al. Tenofovir alafenamide. Ann Pharmacother. 2016;50(11):942–952.
   PubMed Web of Science ®Google Scholar
• Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (evg/cobi/ftc/taf) (genvoya) fixed-dose combination, oral tablet. Ottawa (ON): Common Drug Review, Canadian Agency for Drugs and Technologies in Health; 2016.
   Google Scholar
• Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bictegravir (gs-9883), a novel potent hiv-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60(12):7086–7097.
   PubMed Web of Science ®Google Scholar
• Birkus G, Bam RA, Willkom M, et al. Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors. Antimicrob Agents Chemother. 2016;60(1):316–322.
   PubMed Web of Science ®Google Scholar
• Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. Tenofovir disoproxil fumarate in single tablet regimens for initial hiv-1 therapy: A randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67(1):52–58.
   PubMedGoogle Scholar
• Agarwal K, Fung SK, Nguyen TT, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis b infection. J Hepatol. 2015;62(3):533–540.
   PubMed Web of Science ®Google Scholar
• Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49(5):1898–1906.
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with hiv: week 48 results from the randomised, double-blind, non-inferiority sailing study. Lancet. 2013;382(9893):700–708.
   PubMed Web of Science ®Google Scholar
• Fransen S, Gupta S, Danovich R, et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol. 2009;83(22):11440–11446.
   PubMed Web of Science ®Google Scholar
• Garrido C, Villacian J, Zahonero N, et al. Broad phenotypic cross-resistance to elvitegravir in hiv-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother. 2012;56(6):2873–2878.
   PubMed Web of Science ®Google Scholar
• Fransen S, Gupta S, Frantzell A, et al. Substitutions at amino acid positions 143, 148, and 155 of hiv-1 integrase define distinct genetic barriers to raltegravir resistance in vivo. J Virol. 2012;86(13):7249–7255.
   PubMed Web of Science ®Google Scholar
• Naeger LK, Harrington P, Komatsu T, et al. Effect of dolutegravir functional monotherapy on hiv-1 virological response in integrase strand transfer inhibitor resistant patients. Antivir Ther. 2016;21(6):481–488.
   PubMed Web of Science ®Google Scholar
• Smith SJ, Zhao XZ, Burke TR Jr., et al. Efficacies of cabotegravir and bictegravir against drug-resistant hiv-1 integrase mutants. Retrovirology. 2018;15(1):37.
   PubMed Web of Science ®Google Scholar
• Zhang WW, Cheung PK, Oliviera N, et al. Accumulation of multiple mutations in vivo confers cross-resistance to new and existing integrase inhibitors. J Infect Dis. 2018.
   Web of Science ®Google Scholar
• Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of hiv-1 infection (gs-us-380–1490): A randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073–2082.
   PubMed Web of Science ®Google Scholar
• Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of hiv-1 infection (gs-us-380–489): A double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063–2072.
   PubMed Web of Science ®Google Scholar
• Kristen A, Madeleine W, Ross M, et al. Resistance analyses of bictegravir/emtricitabine/tenofovir alafenamide switch studies. Boston, MA: CROI; 2018.
   Google Scholar
• Acosta RK, White KL, Garner W, et al. Hiv-1 subtype (b or non-b) had no impact on the efficacy of b/f/taf or resistance development in five phase 3 treatment-naïve or switch studies. International AIDS Conference; Amsterdam, Netherlands; 2018.
   Google Scholar
• Kirsten W, Rima K, Madeleine W, et al. Pooled week 48 efficacy and baseline resistance: B/f/taf in treatment-naive patients. Boston, MA: CROI; 2018.
   Google Scholar
• Kristen A, Silvia C, Ross M, et al. Integrase inhibitor resistance selections initiated with drug resistant hiv-1. Boston, MA: CROI; 2018.
   Google Scholar
• Bluma BG, Maureen O, Ruxandra-Ilinca I, et al. In vitro selected resistance to new integrase inhibitors by b and non-b subtype viruses. Boston, MA: CROI; 2018.
   Google Scholar
• Fish MQ, Hewer R, Wallis CL, et al. Natural polymorphisms of integrase among hiv type 1-infected south african patients. AIDS Res Hum Retroviruses. 2010;26(4):489–493.
   PubMed Web of Science ®Google Scholar
• Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the hiv-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther. 2007;12(4):563–570.
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Anthony NJ, Gomez RP, et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of hiv-1 integrase. Proc Natl Acad Sci U S A. 2004;101(31):11233–11238.
   PubMed Web of Science ®Google Scholar
• Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with hiv-1 infection (spring-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927–935.
   PubMed Web of Science ®Google Scholar
• Wijting IEA, Lungu C, Rijnders BJA, et al. Hiv-1 resistance dynamics in patients with virologic failure to dolutegravir maintenance monotherapy. J Infect Dis. 2018;218(5):688–697.
   PubMed Web of Science ®Google Scholar
• Katlama C, Soulie C, Caby F, et al. Dolutegravir as monotherapy in hiv-1-infected individuals with suppressed hiv viraemia. J Antimicrob Chemother. 2016;71(9):2646–2650.
   PubMed Web of Science ®Google Scholar
• Taiwo BO, Zheng L, Stefanescu A, et al. Actg a5353: A pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (hiv-1)-infected participants with hiv-1 rna <500000 copies/ml. Clin Infect Dis. 2018;66(11):1689–1697.
   PubMed Web of Science ®Google Scholar
• Quashie PK, Mesplede T, Han YS, et al. Characterization of the r263k mutation in hiv-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol. 2012;86(5):2696–2705.
   PubMed Web of Science ®Google Scholar
• Brenner BG, Ibanescu RI, Oliveira M, et al. Hiv-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters. J Antimicrob Chemother. 2017;72(8):2171–2183.
   PubMed Web of Science ®Google Scholar
• Wares M, Mesplede T, Quashie PK, et al. The m50i polymorphic substitution in association with the r263k mutation in hiv-1 subtype b integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology. 2014;11(7):1–8.
   PubMedGoogle Scholar
• Gantner P, Lee GQ, Rey D, et al. Dolutegravir reshapes the genetic diversity of hiv-1 reservoirs. J Antimicrob Chemother. 2018;73(4):1045–1053.
   PubMed Web of Science ®Google Scholar
• Stefic K, Salmona M, Capitao M, et al. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an hiv-1-infected child using ultra-deep sequencing. J Antimicrob Chemother. 2017;72(3):850–854.
   PubMed Web of Science ®Google Scholar
• Brado D, Obasa AE, Ikomey GM, et al. Analyses of hiv-1 integrase sequences prior to south african national hiv-treatment program and available of integrase inhibitors in cape town, south africa. Sci Rep. 2018;8(1):4709.
   PubMedGoogle Scholar
• Mesplede T, Quashie PK, Hassounah S, et al. The r263k substitution in hiv-1 subtype c is more deleterious for integrase enzymatic function and viral replication than in subtype b. Aids. 2015;29(12):1459–1466.
   PubMed Web of Science ®Google Scholar
• Rusconi S, Adorni F, Tau P, et al. Dolutegravir (dtg)-containing regimens after receiving raltegravir (ral) or elvitegravir (evg): durability and virological response in a large italian hiv drug resistance network (arca). J Clin Virol. 2018;105:112–117.
   PubMed Web of Science ®Google Scholar
• Acosta R, White K, Garner W et al. Hiv-1 subtype (b or non-b) had no impact on the efficacy of b/f/taf or resistance development in five phase 3 treatment-naïve or switch studies. 22nd International AIDS Conference, Amsterdam, Netherlands; 2018.
   Google Scholar
• Smith SJ, Zhao XZ, Burke TR Jr., et al. Hiv-1 integrase inhibitors that are broadly effective against drug-resistant mutants. Antimicrob Agents Chemother. 2018;62(9). doi: 10.1128/AAC.01035-18.
   Web of Science ®Google Scholar
• Hurt CB, Sebastian J, Hicks CB, et al. Resistance to hiv integrase strand transfer inhibitors among clinical specimens in the united states, 2009–2012. Clin Infect Dis. 2014;58(3):423–431.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Thompson M, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in hiv-1-infected adults. J Acquir Immune Defic Syndr. 2017;75(1):61–66.
   PubMed Web of Science ®Google Scholar
• Sax PE, DeJesus E, Crofoot G, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of hiv-1 infection: A randomised, double-blind, phase 2 trial. Lancet HIV. 2017;4(4): 154–160.
   Web of Science ®Google Scholar
• Sax PE, DeJesus E, Crofoot G, et al. Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide. Aids. 2018;32(12):1723–1725.
   PubMed Web of Science ®Google Scholar
• Prathipati PK, Mandal S, Destache CJ. Development and validation of lc-ms/ms method for quantification of bictegravir in human plasma and its application to an intracellular uptake study. Biomed Chromatogr. 2018. doi: 10.1002/bmc.4379. [Epub ahead of print].
   Web of Science ®Google Scholar
• Aditya GH, Carina R, Eric MJ, et al. Bictegravir/ftc/taf single-tablet regimen in adolescents: week-24 results. Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2018.
   Google Scholar
• Heather Z, Joseph CM, Xuelian W, et al. Clinical pharmacology of the hiv integrase strand transfer inhibitor bictegravir. Seattle, Washington: CROI; 2017.
   Google Scholar
• Podzamczer D, Stellbrink H, Orkin C, et al. B/f/taf versus abc/dtg/3tc or dtg + f/taf in treatment-naïve adults with high baseline viral load or low baseline cd4 count in two phase iii randomized, controlled clinical trials: week 96 results. HIV Drug Ther. Glasgow, UK; 2018.
   Google Scholar
• Stellbrink HJ, Arribas J, Stephens JL, et al. Phase iii randomized, controlled clinical trial of bictegravir coformulated with ftc/taf in a fixed-dose combination (b/f/taf) versus dolutegravir (dtg) + f/taf in treatment-naïve hiv-1 positive adults: week 96. HIV Drug Ther. Glasgow, UK; 2018.
   Google Scholar
• Molina JM, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with hiv-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e357–e365.
   PubMed Web of Science ®Google Scholar
• Wohl D, Clarke A, Maggiolo F, et al. Patient-reported symptoms over 48 weeks among participants in randomized, double-blind, phase iii non-inferiority trials of adults with hiv on co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus co-formulated abacavir, dolutegravir, and lamivudine. Patient. 2018;11(5):561–573.
   PubMedGoogle Scholar
• Andreatta K, Haubrich R, Willkom M, et al. High prevalence of previously undocumented baseline m184v/i does not affect virologic outcome in virologically-suppressed patients switching to bictegravir/emtricitabine/tenofovir/alafenamide (b/f/taf) from a boosted protease inhibitor-based regimen. HIV Drug Ther. 2018. Glassgow, UK.
   Google Scholar
• Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with hiv-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e347–e356.
   PubMed Web of Science ®Google Scholar
• Kityo C, Hagins D, Koenig E, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide in women. Boston, MA: CROI; 2018.
   Google Scholar
• Custodio J, West S, Yu A, et al. Lack of clinically relevant effect of bictegravir (bic, b) on metformin (met) pharmacokinetics (pk) and pharmacodynamics (pd). Open Forum Infect Dis. 2017;4(suppl_1):S429–S429.
   Google Scholar
• Joseph CM, Steve WK, Sean C, et al. Pharmacokinetics of bictegravir administered twice daily in combination with rifampin. Boston, MA: CROI; 2018.
   Google Scholar
• Begley R, Das M, Zhong L, et al. Pharmacokinetics of tenofovir alafenamide when coadministered with other hiv antiretrovirals. J Acquir Immune Defic Syndr. 2018;78(4):465–472.
   PubMed Web of Science ®Google Scholar
• Messiaen P, Wensing AM, Fun A, et al. Clinical use of hiv integrase inhibitors: A systematic review and meta-analysis. PLoS One. 2013;8(1):e52562.
   PubMed Web of Science ®Google Scholar
• Panel on treatment of pregnant women with hiv infection and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in transmission in the united states. U.S. Department of Health and Human Services; 2018. AIDSinfo website: https://aidsinfo.nih.gov/guidelines.
   Google Scholar
• Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 2018.
   PubMed Web of Science ®Google Scholar
• Rebecca Z, Lewis H, Joseph M, et al. Surveillance for neural tube defects following antiretroviral exposure from conception. 22nd International AIDS Conference, Amsterdam, Netherlands; 2018.
   Google Scholar
• Hill A, Clayden P, Thorne C, et al. Safety and pharmacokinetics of dolutegravir in hiv-positive pregnant women: A systematic review. J Virus Erad. 2018;4(2):66–71.
   PubMed Web of Science ®Google Scholar
• Farrow T, Deaton C, Nguyen N, et al. Cumulative safety review of elvitegravir and bictegravir use during pregnancy and risk of neural tube defects. HIV Drug Ther. Glasgow, UK; 2018.
   Google Scholar